Aegerion Pharmaceuticals Inc. (AEGR)
Россия
  • Россия
  • Украина

Aegerion Pharmaceuticals Inc. (AEGR)

Contact Details

1 Main St Ste 8, Cambridge, Massachusetts, USA 02142-1599
(855) 305-2347
1 Main St Ste 8, Cambridge, Massachusetts, USA 02142-1599

General Information

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat lipid disorders. Its products include Lomitapide and Implitapide. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, that is used as an oral once-a-day treatment for patients with severe lipid disorders. Implitapide is used in the treatment of hypertriglyceridemia. Aegerion Pharmaceuticals, Inc. is headquartered in Bridgewater, New Jersey.

Contact Information

Phone(855) 305-2347
Website 1http://www.aegerion.com
Twitter@AegerionPharma
Thomson Reuters PermID4297251280

Executives

NamePositionTotal Annual CompensationYearPercent Change in Compensation
CEO$4,198,5312014-40.3%
CFO$1,520,2362014-19.5%
Other Executive Officer$1,659,95720149.7%
COO$2,539,934201428.3%
Chief Medical Officer$1,622,1112014-47.2%

Government Contracts

Largest Contracts

AgencyProduct or ServiceSigned DateObligation Amount
Department of Veterans AffairsDrugs and BiologicalsAugust 21, 2013$0

Corporate Data

Industries

  • Pharmaceutical Preparation Manufacturing

SIC Industries

  • Pharmaceutical Preparations

Company Size

Sales Volume$240 million
Employees318

Ownership

Ticker SymbolAEGR
ExchangeNASDAQ Global Market
Type of EntityFor Profit Organization
Type of OwnershipNot Tax Exempt Corporate Entity
Year Founded2005

Stocks

Previous Close3.36
Open3.39
Bid3.28 x 200
Ask3.29 x 600
Day`s Range3.23 - 3.45
52-Week Range3.44 - 26.36
Average Volume (1M)790,729
Beta0.7x
Market Cap.$101.38 Million
Last Dividend Amount0
1y Target Price Est.27

Financials

Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue49,00367,30364,19759,384
Cost of Revenue12,01114,48613,99711,838
Gross Profit36,99252,81750,20047,546
Research Development11,31111,28212,4719,798
Selling General and Administrative54,35643,92342,67246,928
Depreciation and Amortization----
Other Operating Expenses----
Total Operating Expenses77,67869,69169,14068,564
Other Income/Expenses Net----
Earnings Before Interest and Taxes(28,675)(2,388)(4,943)(9,180)
Interest Expense6,4927,1137,0696,931
Income Before Tax(35,577)(9,471)(10,896)(15,626)
Income Tax Expense1,022294254199
Minority Interest----
Net Income from Continuing Ops(36,599)(9,765)(11,150)(15,825)
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income(36,599)(9,765)(11,150)(15,825)
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares(36,599)(9,765)(11,150)(15,825)